Why Monopar Therapeutics Inc.’s (MNPR) Stock Is Up 11.69%
As of Friday, August 21, Monopar Therapeutics Inc.’s MNPR share price has surged by 11.69%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Commentary & Analysis
Why Monopar Therapeutics Inc.’s (MNPR) Stock Is Up 5.68%
As of Tuesday, August 04, Monopar Therapeutics Inc.’s MNPR share price has surged by 5.68%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Monopar Therapeutics Inc.’s (MNPR) Stock Is Up 5.21%
As of Thursday, July 30, Monopar Therapeutics Inc.’s MNPR share price has surged by 5.21%, which has investors questioning if this is right time to sell.Michael Rose
Why Monopar Therapeutics Inc.’s (MNPR) Stock Is Down 7.42%
As of Thursday, July 23, Monopar Therapeutics Inc.’s MNPR share price has dipped by 7.42%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Monopar Therapeutics Inc.’s (MNPR) Stock Is Down 5.19%
As of Friday, July 10, Monopar Therapeutics Inc.’s MNPR share price has dipped by 5.19%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | MNPR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $780.5 | $288.9 | 42% |
|
| Shares Out (Mil) | 8.5 | 54.0 | 19% |
|
| Institutional Ownership | 92.0% | 93.1% | 60% |
|
| Float (Mil) | 4.5 | 41.4 | 11% |
|
| Beta | 1.51 | 0.94 | 83% |
|
| Avg Daily Volume (000s) | 168 | 480 | 43% |
|
| Price Change (52-week) |
242.7% | 59.9% | 98% |
|
| Growth | MNPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (16.8%) | (10.1%) | 23% |
|
| EPS (5yr) | 8.4% | 15.9% | 44 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 6.1% | (15.6%) | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 11 | 8 | |
| Current EPS | ($0.837) | ($3.006) | ($1.980) | |
| Month Ago EPS | ($0.766) | ($2.904) | ($3.135) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.766) | ($2.904) | ($3.164) | |
| Year/Year Chg | 34.6% | 62.4% | 36.6% | |
| Financials | MNPR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($18) | ($43) | 25% |
|
| EPS (TTM) | ($2.180) | ($1.500) | 14% |
|
| Operating Cash Flow (TTM) (Mil) | ($12) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | $13 | $2 | 59% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 10% |
|
| Enterprise Value (Q1) (Mil) | $637 | $190 | 36% |
|
| Valuation | MNPR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 5.96 | 2.84 | 82% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MNPR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (18.9%) | (47.7%) | 21% |
|
| ROE | (19.5%) | (55.0%) | 23% |
|
| Liabilities to Assets | 3.1% | 29.6% | 1% |
|
| F-Score | 3 | 3 | 18% |
|
Monopar Therapeutics Inc. did not pass any screens on 9/2/2026.
